BeiGene
BGNE
$293.60
Share price
0.49%
Change (1 day)
31.41%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Market capitalization of BeiGene (BGNE)
Market cap: A$32.12 Billion
As of April 2025 BeiGene has a market cap of A$32.12 Billion. This makes BeiGene the world's 919th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of BeiGene from 2016 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | A$32.12 B | 0.97% |
| 2024 | A$31.81 B | 9.36% |
| 2023 | A$29.08 B | -15.63% |
| 2022 | A$34.47 B | -9.07% |
| 2021 | A$37.91 B | 21.33% |
| 2020 | A$31.25 B | 112.67% |
| 2019 | A$14.69 B | 24.2% |
| 2018 | A$11.83 B | 107.54% |
| 2017 | A$5.70 B | 241.11% |
| 2016 | A$1.67 B |
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 | A$33.22 M | -99.90% | 🇺🇸 USA |
 | A$1.78 B | -94.45% | 🇺🇸 USA |